PRESENTATION

Q3 2022 — Presentation

Q3 2022PDF · 33 pages715 KB
DANAHER CORPORATION
Third Quarter 2022 Earnings Release
October 20, 2022

-- 1 of 33 --

2
Forward Looking Statements
Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s anticipated future financial performance and any other statements regarding events or
developments that we anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could
cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any
such forward-looking statements. These factors include, among other things, the highly uncertain and unpredictable severity, magnitude and duration of the COVID-19 pandemic (and the related
governmental, business and community responses thereto) on our business, results of operations and financial condition, the impact of our debt obligations on our operations and liquidity,
deterioration of or instability in the economy, the markets we serve and the financial markets (including as a result of the COVID-19 pandemic), uncertainties relating to U.S. laws or policies, including
potential changes in U.S. trade policies and tariffs and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and
successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable
laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions
thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic
investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such
acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and
future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our
ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax
laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States
government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks
relating to product manufacturing, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and
surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and
services, the impact of climate change, or legal or regulatory measures to address climate change, labor matters and our ability to recruit, retain and motivate talented employees, international
economic, political, legal, compliance, social and business factors (including the impact of the military conflict between Russia and Ukraine and the impact of the United Kingdom's separation from the
European Union), disruptions relating to man-made and natural disasters (including pandemics such as COVID-19), pension plan costs, inflation and supply chain disruption. Additional information
regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2021 Annual Report on Form 10-K and
Quarterly Report on Form 10-Q for the third quarter of 2022. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the
Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this
presentation or in the “Investors” section of Danaher’s web site, www.danaher.com, under the heading “Financial Reports” and subheading “Quarterly Earnings.” In addition, in addressing various
financial metrics the presentation describes certain of the more significant factors that impacted year-over-year performance. For additional factors that impacted year-over-year performance, please
refer to our earnings release and the other related presentation materials supplementing today’s call, all of which are available in the “Investors” section of Danaher’s web site under the heading
“Financial Reports” and subheading “Quarterly Earnings,” as well as our third quarter 2022 Quarterly Report on Form 10-Q. All references in this presentation (1) to financial metrics relate only to the
continuing operations of Danaher’s business, unless otherwise noted; and (2) to “growth” or other period-to-period changes refer to year-over-year comparisons unless otherwise indicated. We may
also describe certain products and devices which have applications submitted and pending for certain regulatory approvals.

-- 2 of 33 --

Third Quarter 2022 Performance Summary
$7,229 $7,663
Q3 2021 	Q3 2022
$2.39 $2.56
Q3 2021 	Q3 2022
+7.0% +6.0%
Core +10.0%
Acquisitions +1.5%
FX -5.5%
Throughout this presentation, with respect to revenue performance, for the definitions of “Acquisitions," “Core,” and “FX,” please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of
Danaher's website.
($ millions)
ADJUSTED DILUTED NET
EARNINGS PER COMMON SHARE
REVENUE

-- 3 of 33 --

Third Quarter 2022 Performance Summary
18.1%
26.3%
Q3 2021 	Q3 2022
+820 BPS
Core +50 bps
Acquisitions -50 bps
Other +820 bps
Throughout this presentation when referred to in connection with operating profit margins, “Acquisitions” refers to the impact of businesses owned for less than one year or disposed of during such period and not treated as discontinued operations,“Other” refers to the impact of certain third
quarter 2021 acquisition-related fair value adjustments and transaction costs deemed significant associated with the acquisition of Aldevron and a modification and partial termination of a prior commercial arrangement and the resolution of the associated litigation; for further description of these
items, please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website.
OPERATING PROFIT MARGIN

-- 4 of 33 --

Third Quarter 2022: Life Sciences
26.8% 	27.7%
Q3 2021 	Q3 2022
$3,632 $3,776
Q3 2021 	Q3 2022
5
+4.0%
Core +8.0%
Acquisitions +2.5%
FX -6.5%
Core +30 bps
Acquisitions -65 bps
Other +125 bps
+90 BPS
($ millions)
OPERATING PROFIT MARGIN	REVENUE

-- 5 of 33 --

Third Quarter 2022: Diagnostics
5.9%
28.4%
Q3 2021 	Q3 2022
$2,449 $2,679
Q3 2021 	Q3 2022
6
+9.5%
Core +13.5%
Acquisitions +0.5%
FX -4.5%
Core +60 bps
Acquisitions -45 bps
Other +2,235 bps
+2,250 BPS
($ millions)
OPERATING PROFIT MARGIN	REVENUE

-- 6 of 33 --

Third Quarter 2022: Environmental &
Applied Solutions
22.3% 	23.7%
Q3 2021 	Q3 2022
$1,148 $1,208
Q3 2021 	Q3 2022
7
+5.0%
Core +10.5%
FX -5.5%
Core +135 bps
Acquisitions +5 bps
+140 BPS
($ millions)
OPERATING PROFIT MARGIN	REVENUE

-- 7 of 33 --

8
GUIDANCE

-- 8 of 33 --

Q & A
9

-- 9 of 33 --



-- 10 of 33 --

DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES AND SUPPLEMENTAL INFORMATION
THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2022 AND OCTOBER 1, 2021

-- 11 of 33 --

TABLE OF CONTENTS
Page
1 Core Sales Growth by Segment and Base Business Core Sales Growth
2 Forecasted Core Sales Growth, Base Business Core Sales Growth and Adjusted Operating Profit Margin
3 Segment Sales, Operating Profit and Adjusted Operating Profit
4 Adjusted EBITDA and Adjusted EBITDA Margin
8 Other Non-GAAP Adjusted P&L Measures
14 Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
15 Year-Over-Year Core Operating Margin Changes from Continuing Operations
17 Free Cash Flow from Continuing Operations and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations
Conversion Ratio
18 Statement Regarding Non-GAAP Measures
20 Supplemental Information and Quarter Highlights
FORWARD-LOOKING STATEMENTS DISCLOSURE
Statements in this document that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements
within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated
by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the highly uncertain and unpredictable severity,
magnitude and duration of the COVID-19 pandemic (and the related governmental, business and community responses thereto) on our business, results of operations and financial condition, the impact of our debt
obligations on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets (including as a result of the COVID-19 pandemic), uncertainties relating to
U.S. laws or policies, including potential changes in U.S. trade policies and tariffs and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our
ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with
applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof,
our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully
complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other
risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or
other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and
other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities
including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to
commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners,
uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole
sources of supply, the impact of deregulation on demand for our products and services, the impact of climate change, or legal or regulatory measures to address climate change, labor matters and our ability to
recruit, retain and motivate talented employees, international economic, political, legal, compliance, social and business factors (including the impact of the military conflict between Russia and Ukraine and the
impact of the United Kingdom's separation from the European Union), disruptions relating to man-made and natural disasters (including pandemics such as COVID-19), pension plan costs, inflation and supply
chain disruption. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2021 Annual
Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2022. These forward-looking statements speak only as of the date of this document (October 19, 2022) and except to the extent
required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

-- 12 of 33 --

% Change Three-Month Period Ended September 30, 2022 vs. Comparable
2021 Period
Segments
Total Company Life Sciences Diagnostics Environmental &
Applied Solutions
Total sales growth (GAAP) 6.0 % 4.0 % 9.5 % 5.0 %
Impact of:
Acquisitions/divestitures (1.5) % (2.5) % (0.5) % — %
Currency exchange rates 5.5 % 6.5 % 4.5 % 5.5 %
Core sales growth (non-GAAP) 10.0 % 8.0 % 13.5 % 10.5 %
Impact of COVID-19 related testing (1.5) %
Base business core sales growth (non-GAAP) 8.5 %
% Change Nine-Month Period Ended September 30, 2022 vs. Comparable 2021
Period
Segments
Total Company Life Sciences Diagnostics Environmental &
Applied Solutions
Total sales growth (GAAP) 8.5 % 6.5 % 13.0 % 5.0 %
Impact of:
Acquisitions/divestitures (2.0) % (3.5) % (1.0) % 0.5 %
Currency exchange rates 4.0 % 4.5 % 4.0 % 3.5 %
Core sales growth (non-GAAP) 10.5 % 7.5 % 16.0 % 9.0 %
Impact of COVID-19 related testing (2.5) %
Base business core sales growth (non-GAAP) 8.0 %
Note: While we expect overall demand for the Company’s COVID-19 related products to moderate as and to the extent the pandemic subsides, as the pandemic evolves toward endemic
status we believe a level of demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to prevent or mitigate similar, future
pandemics) and COVID-19 testing will continue. However, on a relative basis, we expect the level of ongoing demand for products supporting COVID-19 testing will be subject to more
fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics. Therefore, beginning with the first quarter of 2022, in addition to
disclosing core revenue growth, we disclose “base business core sales growth” on a basis that excludes revenues related to COVID-19 testing and includes revenues from products that
support COVID-19 related vaccines and therapeutics. We believe this additional measure provides useful information to investors by facilitating period-to-period comparisons of our
financial performance and identifying underlying growth trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 testing as a result of the
pandemic.
DANAHER CORPORATION
Core Sales Growth by Segment and Base Business Core Sales Growth
1

-- 13 of 33 --

% Change Three-Month
Period Ending December
31, 2022 vs. Comparable
2021 Period
% Change Year Ending
December 31, 2022 vs.
Comparable 2021
Period
Core sales growth (non-GAAP) Flat to
(low-single digit) +High-single digit
Impact of COVID-19 related testing +High-single to
low-double digit — %
Base business core sales growth (non-GAAP) +High-single digit +High-single digit
Three-Month Period
Ending December 31,
2022 Year Ending December
31, 2022
Adjusted operating profit margin ~30.0 % ~32.0%
1 We do not reconcile these measures to the comparable GAAP measure because of the inherent difficulty in predicting and estimating the future impact and timing of inputs such as
currency translation, acquisitions and divested product lines (which would be reflected in any forecasted GAAP revenue and operating profit).
DANAHER CORPORATION
Forecasted Core Sales Growth, Base Business Core Sales Growth and Adjusted Operating Profit Margin 1
2

-- 14 of 33 --

Sales (GAAP)
Life Sciences $ 3,776 $ 3,632 $ 11,625 $ 10,912
Diagnostics 2,679 2,449 7,884 6,963
Environmental & Applied Solutions 1,208 1,148 3,593 3,430
Total Company $ 7,663 $ 7,229 $ 23,102 $ 21,305
Operating Profit (GAAP)
Life Sciences $ 1,045 $ 975 $ 3,337 $ 3,270
Diagnostics 761 145 2,447 1,420
Environmental & Applied Solutions 286 256 829 821
Other (77) (67) (221) (200)
Total Company $ 2,015 $ 1,309 $ 6,392 $ 5,311
Amortization of Intangible Assets (GAAP)
Life Sciences $ 300 $ 298 $ 931 $ 855
Diagnostics 50 52 151 154
Environmental & Applied Solutions 11 15 38 47
Total Company $ 361 $ 365 $ 1,120 $ 1,056
Other Operating Profit Adjustments 2
Life Sciences $ — $ 45 $ 38 $ 91
Diagnostics — 547 3 557
Environmental & Applied Solutions — — 10 —
Other — — 1 —
Total Company $ — $ 592 $ 52 $ 648
Adjusted Operating Profit (non-GAAP) 3
Life Sciences $ 1,345 $ 1,318 $ 4,306 $ 4,216
Diagnostics 811 744 2,601 2,131
Environmental & Applied Solutions 297 271 877 868
Other (77) (67) (220) (200)
Total Company $ 2,376 $ 2,266 $ 7,564 $ 7,015
Three-Month Period Ended Nine-Month Period Ended
September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted Operating Profit (non-GAAP) is defined as operating profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined).
DANAHER CORPORATION
Segment Sales, Operating Profit and Adjusted Operating Profit
($ in millions)
3

-- 15 of 33 --

Three-Month Period Ended September 30, 2022
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 1,572
Interest, Net 33
Other Nonoperating (Income) Expense 51
Income Taxes 359
Operating Profit (GAAP) $ 1,045 $ 761 $ 286 $ (77) $ 2,015
Other Operating Profit Adjustments 2 — — — — —
Depreciation 69 98 10 2 179
Amortization of Intangible Assets 300 50 11 — 361
Adjusted EBITDA (Non-GAAP) $ 1,414 $ 909 $ 307 $ (75) $ 2,555
Interest, Net (33)
Other Nonoperating Income (Expense) (51)
Income Taxes (359)
Other Operating Profit Adjustments 2 —
Depreciation (179)
Amortization of Intangible Assets (361)
Net Earnings from Continuing Operations (GAAP) $ 1,572
Sales (GAAP) $ 3,776 $ 2,679 $ 1,208 $ 7,663
Net Earnings from Continuing Operations Margin (GAAP) 20.5 %
Adjusted EBITDA Margin (Non-GAAP) 4 37.4 % 33.9 % 25.4 % 33.3 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
4

-- 16 of 33 --

Three-Month Period Ended October 1, 2021
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 1,158
Interest, Net 59
Other Nonoperating (Income) Expense (137)
Income Taxes 229
Operating Profit (GAAP) $ 975 $ 145 $ 256 $ (67) $ 1,309
Other Operating Profit Adjustments 2 45 547 — — 592
Depreciation 71 105 11 2 189
Amortization of Intangible Assets 298 52 15 — 365
Adjusted EBITDA (Non-GAAP) $ 1,389 $ 849 $ 282 $ (65) $ 2,455
Interest, Net (59)
Other Nonoperating Income (Expense) 137
Income Taxes (229)
Other Operating Profit Adjustments 2 (592)
Depreciation (189)
Amortization of Intangible Assets (365)
Net Earnings from Continuing Operations (GAAP) $ 1,158
Sales (GAAP) $ 3,632 $ 2,449 $ 1,148 $ 7,229
Net Earnings from Continuing Operations Margin (GAAP) 16.0 %
Adjusted EBITDA Margin (Non-GAAP) 4 38.2 % 34.7 % 24.6 % 34.0 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
5

-- 17 of 33 --

Nine-Month Period Ended September 30, 2022
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 4,977
Interest, Net 135
Other Nonoperating (Income) Expense 158
Income Taxes 1,122
Operating Profit (GAAP) $ 3,337 $ 2,447 $ 829 $ (221) $ 6,392
Other Operating Profit Adjustments 2 38 3 10 1 52
Depreciation 211 290 31 5 537
Amortization of Intangible Assets 931 151 38 — 1,120
Adjusted EBITDA (Non-GAAP) $ 4,517 $ 2,891 $ 908 $ (215) $ 8,101
Interest, Net (135)
Other Nonoperating Income (Expense) (158)
Income Taxes (1,122)
Other Operating Profit Adjustments 2 (52)
Depreciation (537)
Amortization of Intangible Assets (1,120)
Net Earnings from Continuing Operations (GAAP) $ 4,977
Sales (GAAP) $ 11,625 $ 7,884 $ 3,593 $ 23,102
Net Earnings from Continuing Operations Margin (GAAP) 21.5 %
Adjusted EBITDA Margin (Non-GAAP) 4 38.9 % 36.7 % 25.3 % 35.1 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
6

-- 18 of 33 --

Nine-Month Period Ended October 1, 2021
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 4,559
Interest, Net 172
Other Nonoperating (Income) Expense (374)
Income Taxes 954
Operating Profit (GAAP) $ 3,270 $ 1,420 $ 821 $ (200) $ 5,311
Other Operating Profit Adjustments 2 91 557 — — 648
Depreciation 187 300 33 5 525
Amortization of Intangible Assets 855 154 47 — 1,056
Adjusted EBITDA (Non-GAAP) $ 4,403 $ 2,431 $ 901 $ (195) $ 7,540
Interest, Net (172)
Other Nonoperating Income (Expense) 374
Income Taxes (954)
Other Operating Profit Adjustments 2 (648)
Depreciation (525)
Amortization of Intangible Assets (1,056)
Net Earnings from Continuing Operations (GAAP) $ 4,559
Sales (GAAP) $ 10,912 $ 6,963 $ 3,430 $ 21,305
Net Earnings from Continuing Operations Margin (GAAP) 21.4 %
Adjusted EBITDA Margin (Non-GAAP) 4 40.4 % 34.9 % 26.3 % 35.4 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
7

-- 19 of 33 --

Three-Month Period Ended September 30, 2022
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before income
taxes Income taxes
Net earnings from
continuing
operations for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common
share from
continuing
operations 5
Reported (GAAP) $ 7,663 $ (3,079) 59.8 % $ 2,015 26.3 % $ 1,931 $ (359) $ 1,551 K $ 2.10
Amortization of acquisition-related
intangible assets A — — — 361 4.7 361 361 0.48
Fair value net (gains) losses on
investments B — — — — — 64 64 0.09
Tax effect of the above adjustments H (84) (84) (0.11)
Discrete tax adjustments I (3) (3) —
MCPS "as if converted" J — — — — — — — 21 —
Adjusted (Non-GAAP) $ 7,663 $ (3,079) 59.8 % $ 2,376 31.0 % $ 2,356 $ (446) $ 1,910 $ 2.56
Three-Month Period Ended September 30, 2022
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 7,663 $ (2,149) (28.0) % $ (420) (5.5) % $ (51) $ (33)
Amortization of acquisition-related
intangible assets A — 361 4.7 — — — —
Fair value net (gains) losses on
investments B — — — — — 64 —
Adjusted (Non-GAAP) $ 7,663 $ (1,788) (23.3) % $ (420) (5.5) % $ 13 $ (33)
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
8

-- 20 of 33 --

Three-Month Period Ended October 1, 2021
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before income
taxes Income taxes
Net earnings from
continuing
operations for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common
share from
continuing
operations 5
Reported (GAAP) $ 7,229 $ (2,870) 60.3 % $ 1,309 18.1 % $ 1,387 $ (229) $ 1,117 K $ 1.54
Amortization of acquisition-related
intangible assets A — — — 365 5.0 365 365 0.49
Fair value net (gains) losses on
investments B — — — — — (128) (128) (0.17)
Acquisition-related items E — 17 0.2 45 0.6 45 45 0.06
Contract settlement expense G — — — 547 7.6 547 547 0.73
Tax effect of the above adjustments H (182) (182) (0.24)
Discrete tax adjustments I (23) (23) (0.03)
MCPS "as if converted" J — — — — — — — 41 0.01
Adjusted (Non-GAAP) $ 7,229 $ (2,853) 60.5 % $ 2,266 31.3 % $ 2,216 $ (434) $ 1,782 $ 2.39
Three-Month Period Ended October 1, 2021
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Other
operating
expenses
Other
operating
expenses as a
% of sales
Nonoperating
income (expense),
net (excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 7,229 $ (2,062) (28.5) % $ (441) (6.1) % $ (547) (7.6) % $ 137 $ (59)
Amortization of acquisition-related
intangible assets A — 365 5.0 — — — — — —
Fair value net (gains) losses on
investments B — — — — — — — (128) —
Acquisition-related items E — 28 0.4 — — — — — —
Contract settlement expense G — — — — — 547 7.6 — —
Adjusted (Non-GAAP) $ 7,229 $ (1,669) (23.1) % $ (441) (6.1) % $ — — % $ 9 $ (59)
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
9

-- 21 of 33 --

Nine-Month Period Ended September 30, 2022
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before income
taxes Income taxes
Net earnings from
continuing
operations for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common share
from
continuing
operations 5
Reported (GAAP) $ 23,102 $ (9,092) 60.6 % $ 6,392 27.7 % $ 6,099 $ (1,122) $ 4,913 K $ 6.67
Amortization of acquisition-related
intangible assets A — — — 1,120 4.8 1,120 1,120 1.50
Fair value net (gains) losses on
investments B — — — — — 186 186 0.25
Impairments and other charges C — 18 0.1 52 0.2 52 52 0.07
Loss on partial settlement of a defined
benefit plan D — — — — — 10 10 0.01
Tax effect of the above adjustments H (267) (267) (0.36)
Discrete tax adjustments I (52) (52) (0.07)
MCPS "as if converted" J — — — — — — — 64 0.01
Adjusted (Non-GAAP) $ 23,102 $ (9,074) 60.7 % $ 7,564 32.7 % $ 7,467 $ (1,441) $ 6,026 $ 8.08
Nine-Month Period Ended September 30, 2022
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 23,102 $ (6,326) (27.4) % $ (1,292) (5.6) % $ (158) $ (135)
Amortization of acquisition-related
intangible assets A — 1,120 4.8 — — — —
Fair value net (gains) losses on
investments B — — — — — 186 —
Impairments and other charges C — 34 0.1 — — — —
Loss on partial settlement of a defined
benefit plan D — — — — — 10 —
Rounding — — 0.1 — — — —
Adjusted (Non-GAAP) $ 23,102 $ (5,172) (22.4) % $ (1,292) (5.6) % $ 38 $ (135)
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
10

-- 22 of 33 --

Nine-Month Period Ended October 1, 2021
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before income
taxes Income taxes
Net earnings from
continuing
operations for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common share
from
continuing
operations 5
Reported (GAAP) $ 21,305 $ (8,296) 61.1 % $ 5,311 24.9 % $ 5,513 $ (954) $ 4,495 K $ 6.10
Amortization of acquisition-related
intangible assets A — — — 1,056 5.0 1,056 1,056 1.42
Fair value net (gains) losses on
investments B — — — — — (330) (330) (0.44)
Impairments and other charges C — — — 10 — 10 10 0.01
Acquisition-related items E 17 46 0.3 91 0.4 91 91 0.12
Gain on disposition of certain product
lines F — — — — — (13) (13) (0.02)
Contract settlement expense G — — — 547 2.6 547 547 0.73
Tax effect of the above adjustments H (292) (292) (0.39)
Discrete tax adjustments I (143) (143) (0.19)
MCPS "as if converted" J — — — — — — — 64 0.02
Rounding — — (0.1) — — — — — —
Adjusted (Non-GAAP) $ 21,322 $ (8,250) 61.3 % $ 7,015 32.9 % $ 6,874 $ (1,389) $ 5,485 $ 7.36
Nine-Month Period Ended October 1, 2021
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Other
operating
expenses
Other
operating
expenses as a
% of sales
Nonoperating
income (expense),
net (excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 21,305 $ (5,904) (27.7) % $ (1,247) (5.9) % $ (547) (2.6) % $ 374 $ (172)
Amortization of acquisition-related
intangible assets A — 1,056 5.0 — — — — — —
Fair value net (gains) losses on
investments B — — — — — — — (330) —
Impairments and other charges C — 10 — — — — — — —
Acquisition-related items E 17 28 0.1 — — — — — —
Gain on disposition of certain product
lines F — — — — — — — (13) —
Contract settlement expense G — — — — — 547 2.6 — —
Rounding — — — — 0.1 — — — —
Adjusted (Non-GAAP) $ 21,322 $ (4,810) (22.6) % $ (1,247) (5.8) % $ — — % $ 31 $ (172)
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
11

-- 23 of 33 --

A Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in
the amortization line item above):
Three-Month Period Ended Nine-Month Period Ended
September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021
Pretax $ 361 $ 365 $ 1,120 $ 1,056
After-tax 293 293 904 842
B Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax
amounts set forth below are reflected in the fair value net (gains) losses on investments line above):
Three-Month Period Ended Nine-Month Period Ended
September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021
Pretax $ 64 $ (128) $ 186 $ (330)
After-tax 48 (97) 141 (258)
C Impairment charges related to technology and customer relationships in the Environmental & Applied Solutions segment recorded in the nine-month period
ended September 30, 2022 ($9 million pretax as reported in this line item, $7 million after-tax). Additionally, in the nine-month period ended September 30,
2022, charges incurred primarily related to impairments of accounts receivable and inventory as well as accruals for contractual obligations in Russia
($43 million pretax as reported in this line item, $40 million after-tax). Impairment charges related to a trade name in the Diagnostics segment recorded in the
nine-month period ended October 1, 2021 ($10 million pretax as reported in this line item, $8 million after-tax).
D Loss on a partial settlement of a defined benefit plan as a result of the transfer of a portion of the Company’s non-U.S. pension liabilities related to one defined
benefit plan to a third-party in the nine-month period ended September 30, 2022 ($10 million pretax as reported in this line item, $9 million after-tax).
E Costs incurred for fair value adjustments to inventory and transaction costs deemed significant related to the acquisition of Aldevron in the three-month period
ended October 1, 2021 ($45 million pretax as reported in this line item, $36 million after-tax). Costs incurred for fair value adjustments to inventory and deferred
revenue and transaction costs deemed significant related to the acquisitions of Cytiva and Aldevron in the nine-month period ended October 1, 2021 ($91 million
pretax as reported in this line item, $72 million after-tax). The Company deems acquisition-related transaction costs incurred in a given period to be significant
(generally relating to the Company’s larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for
Danaher in a given period.
F Gain on disposition of certain product lines in the nine-month period ended October 1, 2021 ($13 million pretax as reported in this line item, $10 million after-
tax).
G Expense related to the modification and partial termination of a prior commercial arrangement and resolution of the associated litigation in both the three and
nine-month periods ended October 1, 2021 ($547 million pretax as reported in this line item, $415 million after-tax).
H This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above
indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall
estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application
of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. The MCPS
dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.
I Discrete tax adjustments and other tax-related adjustments for the three-month period ended September 30, 2022, include the impact of net discrete tax benefits
of $3 million related primarily to excess tax benefits from stock-based compensation partially offset by changes in estimates associated with prior period
uncertain tax positions. Discrete tax adjustments and other tax-related adjustments for the nine-month period ended September 30, 2022, include the impact of
net discrete tax benefits of $52 million related primarily to excess tax benefits from stock-based compensation and changes in estimates associated with prior
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
12

-- 24 of 33 --

period uncertain tax positions. Discrete tax adjustments and other tax-related adjustments for the three-month period ended October 1, 2021, include the impact
of net discrete tax benefits of $23 million related primarily to excess tax benefits from stock-based compensation, audit settlements and a higher tax benefit
associated with the pretax charge in the quarter related to the modification and partial termination of a commercial arrangement and the resolution of the
associated litigation. Discrete tax adjustments and other tax-related adjustments for the nine-month period ended October 1, 2021, include the impact of net
discrete tax benefits of $143 million related primarily to the release of reserves for uncertain tax positions due to the expiration of statutes of limitation, audit
settlements, excess tax benefits from stock-based compensation and a higher tax benefit associated with the pretax charge in the period related to the modification
and partial termination of a commercial arrangement and the resolution of the associated litigation, net of changes in estimates associated with prior period
uncertain tax positions.
J In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of 4.75% MCPS Series A. In May 2020, the Company issued $1.72 billion
in aggregate liquidation preference of 5.0% MCPS Series B. Dividends on the MCPS Series A were, and on the Series B are, payable on a cumulative basis at an
annual rate of 4.75% and 5.0%, respectively, on the liquidation preference of $1,000 per share. Each share of MCPS Series A converted on April 15, 2022 into
6.6632 shares of Danaher’s common stock. Unless earlier converted, each share of MCPS Series B will automatically convert on April 15, 2023 into between
5.0143 and 6.1425 shares of Danaher’s common stock, subject to further anti-dilution adjustments. The number of shares of Danaher’s common stock issuable
on conversion of the MCPS is determined based on the volume weighted average price (“VWAP”) per share of the Company's common stock over the 20
consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately before April 15, 2023 for the Series B. For the
calculation of net earnings per common share from continuing operations, the impact of the dilutive MCPS is calculated under the if-converted method and the
related MCPS dividends are excluded. For the purposes of calculating adjusted earnings per common share from continuing operations, the Company has
excluded the paid and anticipated MCPS cash dividends and assumed the “if-converted” method of share dilution (the incremental shares of common stock
deemed outstanding applying the “if-converted” method of calculating share dilution only with respect to any MCPS the conversion of which would be dilutive
in the particular period are referred to as the “Converted Shares”) for any MCPS that were anti-dilutive for the given period. For additional information about the
impact of the MCPS on the calculation of diluted EPS, see note 6 in the Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
table below.
K Net earnings from continuing operations for calculation of diluted earnings per common share is summarized as follows ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021
Net earnings from continuing operations $ 1,572 $ 1,158 $ 4,977 $ 4,559
MCPS dividends (21) (41) (84) (123)
Net earnings from continuing operations attributable to common stockholders for
Basic EPS 1,551 1,117 4,893 4,436
Adjustment for MCPS dividends for dilutive MCPS — — 20 59
Net earnings from continuing operations attributable to common stockholders after
assumed conversions for Diluted EPS $ 1,551 $ 1,117 $ 4,913 $ 4,495
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
13

-- 25 of 33 --

Forecasted
Three-Month Period Ended Nine-Month Period Ended Three-Month
Period Ending Year Ending
September 30,
2022 October 1, 2021 September 30,
2022 October 1, 2021 December 31,
2022 December 31,
2022
Average common stock and common equivalent shares
outstanding - diluted (GAAP) 6 737.4 727.0 737.0 736.4 739.9 737.7
Converted shares 7 8.6 19.6 8.6 8.6 8.6 8.6
Adjusted average common stock and common equivalent shares
outstanding - diluted (non-GAAP) 746.0 746.6 745.6 745.0 748.5 746.3
6 The impact of the MCPS Series A calculated under the if-converted method was dilutive for the nine-month periods ended September 30, 2022 and October 1, 2021, and as such 4.0
million shares and 11.0 million shares, respectively, underlying the MCPS Series A were included in the calculation of diluted EPS. The related MCPS Series A dividends of $20 million
and $59 million for the nine-month periods ended September 30, 2022 and October 1, 2021, respectively, were excluded from the calculation of net earnings for diluted EPS. The impact
of the MCPS Series A calculated under the if-converted method was anti-dilutive for the three-month period ended October 1, 2021, and as such 11.0 million shares underlying the MCPS
Series A were excluded from the calculation of diluted EPS for the three-month period and the related MCPS Series A dividends of $19 million were included in the calculation of net
earnings for diluted EPS for the period. On April 15, 2022, all outstanding shares of the MCPS Series A converted into 11.0 million shares of the Company’s common stock. There were
no MCPS Series A dividends declared in the second quarter of 2022 prior to their conversion and the MCPS Series A were dilutive for all periods prior to the conversion.
Additionally, for the year ending December 31, 2022, the impact of the MCPS Series A calculated under the if-converted method is forecasted to be dilutive and as such, approximately 3.0
million shares for the period underlying the MCPS Series A are included in the calculation of diluted EPS.
The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for both the three and nine-month periods ended September 30, 2022 and October 1, 2021,
and as such 8.6 million shares, for both the three and nine-month periods underlying the MCPS Series B were excluded from the calculation of diluted EPS and the related MCPS Series B
dividends of $21 million and $22 million for the three-month periods, respectively, and $64 million for both nine-month periods were included in the calculation of net earnings for diluted
EPS.
Additionally, for both the three-month period and year ending December 31, 2022, the impact of the MCPS Series B calculated under the if-converted method is forecasted to be anti-
dilutive and as such, approximately 8.6 million shares for both periods underlying the MCPS Series B are excluded from the calculation of diluted EPS.
7 The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using an average 20
trading-day trailing VWAP of $274.64 and $320.10 as of September 30, 2022 and October 1, 2021, respectively.
DANAHER CORPORATION
Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
(shares in millions)
14

-- 26 of 33 --

Segments
Total Company Life Sciences Diagnostics
Environmental
& Applied
Solutions
Three-Month Period Ended October 1, 2021 Operating Profit Margins from Continuing
Operations (GAAP) 18.10 % 26.80 % 5.90 % 22.30 %
Third quarter 2022 impact from operating profit margins of businesses that have been owned for
less than one year (0.50) (0.65) (0.45) 0.05
Third quarter 2021 acquisition-related fair value adjustments to inventory and transaction costs
deemed significant related to the acquisition of Aldevron 0.65 1.25 — —
Third quarter 2021 impact of the modification and partial termination of a prior commercial
arrangement and resolution of the associated litigation 7.55 — 22.35 —
Year-over-year core operating profit margin changes for the third quarter 2022 (defined as all
year-over-year operating profit margin changes other than the changes identified in the line
items above) (non-GAAP) 0.50 0.30 0.60 1.35
Three-Month Period Ended September 30, 2022 Operating Profit Margins from Continuing
Operations (GAAP) 26.30 % 27.70 % 28.40 % 23.70 %
Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it
determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
DANAHER CORPORATION
Year-Over-Year Core Operating Margin Changes from Continuing Operations
15

-- 27 of 33 --

Segments
Total Company Life Sciences Diagnostics
Environmental
& Applied
Solutions
Nine-Month Period Ended October 1, 2021 Operating Profit Margins from Continuing
Operations (GAAP) 24.90 % 30.00 % 20.40 % 23.90 %
First nine months of 2022 impact from operating profit margins of businesses that have been
owned for less than one year or were disposed of during such period and did not qualify as
discontinued operations (0.40) (1.10) 0.10 0.25
First nine months of 2022 impairments of accounts receivable and inventory as well as accruals
for contractual obligations in Russia (0.15) (0.35) (0.05) —
Second quarter 2022 impairment charge related to technology and customer relationships in the
Environmental & Applied Solutions segment, net of first quarter 2021 impairment charge related
to a trade name in the Diagnostics segment — — 0.15 (0.25)
First nine months of 2021 acquisition-related fair value adjustments to inventory and transaction
costs deemed significant related to the acquisition of Aldevron 0.20 0.40 — —
First nine months of 2021 acquisition-related fair value adjustments to inventory and deferred
revenue related to the acquisition of Cytiva 0.25 0.40 — —
Third quarter 2021 impact of the modification and partial termination of a prior commercial
arrangement and resolution of the associated litigation 2.55 — 7.85 —
Year-over-year core operating profit margin changes for first nine months of 2022 (defined as
all year-over-year operating profit margin changes other than the changes identified in the line
items above) (non-GAAP) 0.35 (0.65) 2.55 (0.80)
Nine-Month Period Ended September 30, 2022 Operating Profit Margins from Continuing
Operations (GAAP) 27.70 % 28.70 % 31.00 % 23.10 %
Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it
determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
DANAHER CORPORATION
Year-Over-Year Core Operating Margin Changes from Continuing Operations
16

-- 28 of 33 --

Three-Month Period Ended Year-over-Year
Change
Nine-Month Period Ended Year-over-Year
Change	September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021
Total Cash Flows from Continuing Operations:
Net cash provided by operating activities from continuing
operations (GAAP) $ 2,010 $ 2,034 $ 5,978 $ 6,025
Total cash used in investing activities from continuing
operations (GAAP) $ (515) $ (10,048) $ (1,418) $ (12,108)
Total cash (used in) provided by financing activities from
continuing operations (GAAP) $ (230) $ 3,305 $ (1,664) $ 2,717
Free Cash Flow from Continuing Operations:
Net cash provided by operating activities from continuing
operations (GAAP) $ 2,010 $ 2,034 ~ (1.0) % $ 5,978 $ 6,025 ~ (1.0) %
Less: payments for additions to property, plant &
equipment (capital expenditures) from continuing
operations (GAAP) (277) (318) (823) (874)
Plus: proceeds from sales of property, plant & equipment
(capital disposals) from continuing operations (GAAP) — — 9 13
Free cash flow from continuing operations (non-GAAP) $ 1,733 $ 1,716 ~ 1.0 % $ 5,164 $ 5,164 — %
Free Cash Flow from Continuing Operations to Net
Earnings from Continuing Operations Conversion
Ratio:
Free cash flow from continuing operations from above
(non-GAAP) $ 1,733 $ 1,716 $ 5,164 $ 5,164
Net earnings from continuing operations (GAAP) 1,572 1,158 4,977 4,559
Free cash flow from continuing operations to net earnings
from continuing operations conversion ratio (non-GAAP) 1.10 1.48 1.04 1.13
We define free cash flow from continuing operations as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing
operations (“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”). All amounts presented above reflect only
continuing operations.
DANAHER CORPORATION
Free Cash Flow from Continuing Operations and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Conversion Ratio
($ in millions)
17

-- 29 of 33 --

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may
not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering
additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the corresponding GAAP measure, help our investors
to:
• with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior
and future periods and to our peers;
• with respect to core sales and related sales measures, identify underlying growth trends in our business and compare our sales performance with prior and future
periods and to our peers; and
• with respect to free cash flow from continuing operations and related cash flow measures (the “FCF Measure”), understand Danaher’s ability to generate cash
without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities
(although a limitation of free cash flow is that it does not take into account the Company’s debt service requirements and other non-discretionary expenditures,
and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).
While we expect overall demand for the Company’s COVID-19 related products to moderate as and to the extent the pandemic subsides, as the pandemic evolves toward
endemic status we believe a level of demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to
prevent or mitigate similar, future pandemics) and COVID-19 testing will continue. However, on a relative basis, we expect the level of ongoing demand for products
supporting COVID-19 testing will be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and
therapeutics. Therefore, beginning with the first quarter of 2022, in addition to disclosing core revenue growth, we disclose “base business core sales growth” on a basis
that excludes revenues related to COVID-19 testing and includes revenues from products that support COVID-19 related vaccines and therapeutics. We believe this
additional measure provides useful information to investors by facilitating period-to-period comparisons of our financial performance and identifying underlying growth
trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 testing as a result of the pandemic.
Management uses these non-GAAP measures to measure the Company’s operating and financial performance, and uses core sales and non-GAAP measures similar to
Adjusted Diluted Net Earnings Per Common Share from Continuing Operations and the FCF Measure in the Company’s executive compensation program.
• The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
◦ Amortization of Intangible Assets. We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges
are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition
activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to intangible assets and related
amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense
facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive
and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales
generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully
amortized.
◦ Restructuring Charges. We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic
nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from
application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of
our business and we believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs to facilitate a more
consistent comparison of operating results over time.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
18

-- 30 of 33 --

◦ Other Adjustments. With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we
exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's
commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-
term performance difficult. For example, we excluded the first quarter 2022 charge for asset impairments, accruals for contractual obligations and
similar items related to our Russia operations because, even though it is possible we could incur additional charges in the future, we do not believe these
charges are indicative of Danaher’s ongoing operating costs.
• With respect to adjusted average common stock and common equivalent shares outstanding, Danaher’s Mandatory Convertible Preferred Stock (“MCPS”) Series
A converted into Danaher common stock on April 15, 2022 and MCPS Series B will mandatorily convert into Danaher common stock on the mandatory
conversion date, which is expected to be April 15, 2023 (unless converted or redeemed earlier in accordance with the terms of the applicable certificate of
designations). With respect to the calculation of Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we apply the “if converted”
method of share dilution to the MCPS Series A and B in all applicable periods irrespective of whether such preferred shares would be dilutive or anti-dilutive in
the period. We believe this presentation provides useful information to investors by helping them understand what the net impact will be on Danaher’s earnings
per share-related measures once the MCPS convert into Danaher common stock.
• With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to the “other adjustments”, we exclude
the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued operations) because the timing, size,
number and nature of such transactions can vary significantly from period to period and may obscure underlying business trends and make comparisons of long-
term performance difficult.
• We calculate adjusted EBITDA by adding to operating profit amounts equal to depreciation and amortization and making the other adjustments reflected in the
applicable tables above, which allows us to calculate and disclose such measure by segment. Given Danaher’s diversification, we believe this helps our investors
compare the profitability of our individual segments to peer companies with like business lines.
• With respect to core sales related measures, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to
volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number
and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business
trends and make comparisons of long-term performance difficult.
• With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate
the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements.
With respect to forecasted core sales related measures, we do not reconcile these measures to the comparable GAAP measure because of the inherent difficulty in
predicting and estimating the future impact and timing of currency translation, acquisitions and divested product lines, which would be reflected in any forecasted GAAP
revenue.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
19

-- 31 of 33 --

Three-Month
Period Ending
December 31, 2022 Year Ending
December 31, 2022
COVID-19 testing sales ~$375 ~$2,900
Impact of currency exchange rates on sales 8 ~$(500) ~$(1,400)
Operating profit fall-through 9 ~25.0%
Corporate expense 10 ~$(75)
Non-service components of periodic benefit costs (as included in Other income (expense), net in the Consolidated Condensed
Statements of Earnings) ~$10 - $15
Interest expense, net 11 ~$(35) - $(40)
Effective tax rate ~19.3 %
8 This line item is not a forecast. The impact to the Company’s sales for the indicated periods is calculated using the assumption that the currency exchange rates in effect as of October 18,
2022 prevail throughout the remainder of 2022, and estimates the impact to the Company’s sales for the indicated periods based on such assumptions.
9 Operating profit fall-through is defined as the percentage that results from dividing the assumed increase in operating profit (from incremental period-over-period sales) by the amount of
incremental period-over-period sales. This line item is not a forecast and the operating profit fall-through is calculated assuming the forecasted core sales growth and the currency
exchange rates described in note 8 above.
10 Corporate expense represents the operating profit (GAAP) for the Other segment, which consists of unallocated corporate costs and other costs not considered part of management’s
evaluation of reportable segment operating performance.
11 Interest expense, net is defined as interest expense net of interest income. This line item is an assumption rather than a forecast. The estimated interest expense, net is calculated assuming
the currency exchange rates in effect as of September 30, 2022 are to prevail throughout the remainder of the period indicated and assuming interest rate increases in the period indicated.
Quarter Highlights
Q3 2022 Core Revenue Growth by Segment
• Life Sciences +8.0%
◦ Bioprocessing better than anticipated, continue to expect high-single digit core growth for the year
◦ Life Science Instruments base business +low-double digit
◦ Genomics businesses +double-digit
• Diagnostics +13.5%
◦ Cepheid nearly +30% and LBS +mid-teens
• Environmental & Applied Solutions +10.5%
◦ Water Quality +mid-teens
◦ Product Identification +low-single digit
DANAHER CORPORATION
Supplemental Information and Quarter Highlights
($ in millions)
20

-- 32 of 33 --

21

-- 33 of 33 --